← All trials
NCT01497873
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2010
- Primary completion
- Dec 1, 2017
- Completion date
- Dec 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 176
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Chong Kun Dang PharmaceuticalLead sponsor
- Seoul Veterans HospitalOverall official - principal investigator
- University of UlsanOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- The National Cancer CenterOverall official - principal investigator
- Ajou UniversityOverall official - principal investigator
- Chonbuk National UniversityOverall official - principal investigator
- Keimyung UniversityOverall official - principal investigator
- Kyung Hee UniversityOverall official - principal investigator
- Chung-Ang UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.